vendredi 28 juillet 2017

Onco Actu du 28 juillet 2017

1. Biologie

First draft of a genome-wide cancer ‘dependency map’ [Harvard Gazette]

Systematically exposing vulnerabilities of cancer cells [Novartis]

Enhancers Drive Pancreatic Cancer Metastasis: Study [The Scientist]

3.1.1 Tabac - e-cigs

Study links rising U.S. e-cigarette use to rise in smokers quitting [Reuters]

3.5 Prévention - UV

Tans — even from a new drug — aren’t the way to prevent skin cancer [STAT]

4. Dépistage, diagnostic et pronostic

Differences in Subtypes of Gastric Cancer May Determine Prognosis and Response to Treatment [AACR]

5. Traitements

Tumors caused by pluripotent stem cells can be tackled with radiation, say Stanford researchers [Stanford Medicine]

Stem cell treatment kills cancer cells that have spread in mice [Cancer Research UK]

New strategy against childhood cancer [Karolinska Institutet]

5.10 Traitements - Essais

Tagrisso significantly improves progression-free survival in the Phase III FLAURA trial for lung cancer [AstraZeneca]

5.12.3 Immunothérapies-combinaisons

Why I Don’t Favor an Front-Loaded Approach for Most Advanced NSCLC Patients [Cancer Grace]

5.12.4 Immunothérapies - Essais

Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails [Xconomy]

AstraZeneca Gets the Bad News [In the Pipeline]

AstraZeneca's Mystic shortfall is an immuno-oncology shake-up for Bristol-Myers and a bolster for Merck and Roche [Fierce Pharma]

AstraZeneca lung cancer immunotherapy trial failure sends shares plunging [STAT]

AstraZeneca's Missing Takeover Defense [Bloomberg]

AstraZeneca lung cancer failure sparks 16 percent share fall [Reuters]

AstraZeneca’s Cancer Drug Trial Disappoints, Sending Shares Lower [NY Times]

AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails and shares plunge [EndPoints]

AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer [AstraZeneca]

5.12.5 Immunothérapies - Pharma

Cancer drug war heats up as Big Pharma squares off against Genentech [San Francisco Business Times]

The Keytruda Story [In the Pipeline]

Bristol-Myers shares slump after failed AstraZeneca drug trial [Reuters]

The Startling History Behind Merck's New Cancer Blockbuster [Forbes]

5.2 Pharma

Astellas Announces Wind-Down of Agensys Research Operations [Astellas]

Astellas winds down Agensys, turning its back on antibody-drug conjugate research [Fierce Biotech]

Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech [EndPoints]

5.2.1 Pharma - Partenariats

Tesaro Cashes In Again on PARP Blocker With $100M Takeda Deal [Xconomy]

5.2.2 Pharma - Fusions & Acquisitions

As drug prices drop, generics makers fight back with deals [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Don’t limit the powers of the FDA [Boston Globe]

US, EU filings for Eisai’s lenvatinib in liver cancer [Pharma Times]

5.4 Traitements - Economie

NICE approval for nivolumab provides new treatment for advanced blood cancer [NICE]

After NICE setback, Roche strikes deal for Gazyvaro coverage in U.K. [Fierce Pharma]

NICE backs Roche’s Gazyvaro for follicular lymphoma [Pharma Times]

6. Lutte contre les cancers

Finding the signal in the noise of hospital quality metrics [The Incidental Economist]

6.1 Observation

Overweight at 17? Your Colon Cancer Risk Rises [NY Times]

Adult colorectal cancer risk tied to weight as a teen [Reuters]

6.11 Patients

What Advances are Researchers Making in Treating Glioblastoma, McCain’s Cancer? [AACR]

Dear Sen. McCain: Here’s what I’ve learned from living with glioblastoma [STAT]

6.3 Associations/Fondations

Cancer Research UK: Taking a broad view of research impact [BioMed Central blog]

6.7.2 Applis

FDA Announces New Steps to Empower Consumers and Advance Digital Healthcare [FDA Voice]

6.7.3 DMP

Amazon has a secret health tech team called 1492 working on medical records, virtual doc visits [CNBC]

6.9 Controverses

New "p < 0.005" Standard Considered Harmful [Multa Verba]